The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
复制标题
DOI:
10.1002/mus.23902
复制
发表时间:
2013-09
期刊:
影响因子:
3.4
通讯作者:
Peltz, Stuart
中科院分区:
文献类型:
--
作者:
Mcdonald, Craig M.;Henricson, Erik K.;Abresch, R. Ted;Florence, Julaine M.;Eagle, Michelle;Gappmaier, Eduard;Glanzman, Allan M.;Spiegel, Robert;Barth, Jay;Elfring, Gary;Reha, Allen;Peltz, Stuart
关键词:
Introduction: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followed for 48 weeks in a multicenter, randomized, double-blind, placebo-controlled trial of ataluren. Placebo arm data (N = 57) provided insight into the natural history of the 6-minute walk test (6MWT) and other endpoints. Methods: Evaluations performed every 6 weeks included the 6-minute walk distance (6MWD), timed function tests (TFTs), and quantitative strength using hand-held myometry. Results: Baseline age (≥7 years), 6MWD, and selected TFT performance are strong predictors of decline in ambulation (Δ6MWD) and time to 10% worsening in 6MWD. A baseline 6MWD of <350 meters was associated with greater functional decline, and loss of ambulation was only seen in those with baseline 6MWD <325 meters. Only 1 of 42 (2.3%) subjects able to stand from supine lost ambulation. Conclusion: Findings confirm the clinical meaningfulness of the 6MWD as the most accepted primary clinical endpoint in ambulatory DMD trials.
登录
查看更多内容
影响因子:
9.9
作者:
BROOKE, MH;FENICHEL, GM;ARFKEN, C
通讯作者:
ARFKEN, C
影响因子:
158.5
作者:
Goemans, Nathalie M.;Tulinius, Mar;van Deutekom, Judith C.
通讯作者:
van Deutekom, Judith C.
影响因子:
--
作者:
Crespo, CJ;Keteyian, SJ;Sempos, CT
通讯作者:
Sempos, CT
影响因子:
2.8
作者:
Mazzone, Elena;Martinelli, Diego;Mercuri, Eugenio
通讯作者:
Mercuri, Eugenio
影响因子:
2.8
作者:
Beenakker, EAC;van der Hoeven, JH;Maurits, NM
通讯作者:
Maurits, NM